For instance, combining metabolic inhibitors with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) can reduce lactate accumulation, alleviating immunosuppression and enhancing tumor responsiveness to immunotherapy (48, 53). Here, CD274 is linked to neoplasm.